Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.

Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group.

Clin Cancer Res. 2012 Apr 15;18(8):2290-300. doi: 10.1158/1078-0432.CCR-11-2175. Epub 2012 Feb 28.

2.

Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T.

Eur J Cancer. 2012 Mar;48(4):465-74. doi: 10.1016/j.ejca.2011.12.026. Epub 2012 Jan 27.

PMID:
22285181
3.

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Awada A, Gil T, Whenham N, Van Hamme J, Besse-Hammer T, Brendel E, Delesen H, Joosten MC, Lathia CD, Loembé BA, Piccart-Ghebart M, Hendlisz A.

J Clin Pharmacol. 2011 Dec;51(12):1674-84. doi: 10.1177/0091270010386226. Epub 2011 Jan 5.

PMID:
21209247
4.

The value, qualification, and regulatory use of surrogate end points in drug development.

Lathia CD, Amakye D, Dai W, Girman C, Madani S, Mayne J, MacCarthy P, Pertel P, Seman L, Stoch A, Tarantino P, Webster C, Williams S, Wagner JA.

Clin Pharmacol Ther. 2009 Jul;86(1):32-43. doi: 10.1038/clpt.2009.69. Epub 2009 May 27. Review.

PMID:
19474783
5.

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.

Molina JR, Reid JM, Erlichman C, Sloan JA, Furth A, Safgren SL, Lathia CD, Alberts SR.

Anticancer Drugs. 2005 Oct;16(9):997-1002.

PMID:
16162976
6.
7.

Development of a chiral HPLC method to evaluate in vivo enantiomeric inversion of an unstable, polar radiosensitizer in plasma.

Kagel JR, Rossi DT, Hoffman KL, Leja B, Lathia CD.

J Pharm Biomed Anal. 1999 Nov;21(3):527-34.

PMID:
10701419
8.

Validated HPLC/MS/MS assay for CI-1011 in rat plasma and a comparison with an HPLC/UV assay.

Bullen WW, Lathia CD, Abel RB, Hayes RN.

J Pharm Biomed Anal. 1998 Sep;17(8):1399-413.

PMID:
9800659
9.

An HPLC assay utilizing solid-phase extraction for CI-1010, an alkylating radiosensitizer, in rat plasma.

Bullen WW, Rossi DT, Hoffman KL, Suri A, Lathia CD.

J Pharm Biomed Anal. 1997 Sep;16(1):47-55.

PMID:
9447551
10.
11.

A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.

Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH.

Invest New Drugs. 1997;15(3):235-46.

PMID:
9387046

Supplemental Content

Loading ...
Support Center